Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVX836 Phase 2a Booster vs Primary Vaccination Study in Adults
2024-516267-83-00Phase 2Completed
- Sponsor
- Osivax
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OVX836 in influenza (2 arms), sponsored by Osivax. Started Oct 2024; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on 2024-516267-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516267-83-00.